Vir Biotechnology Q2 Earnings Call Highlights

Vir Biotechnology NASDAQ: VIR reported second-quarter 2026 results alongside updates on its chronic hepatitis delta and oncology programs, highlighting completed enrollment in a key hepatitis delta study, plans for multiple data readouts, and expanded development activity for its prostate cancer candidate VIR-5500.

MarketBeat • Aug 6, 2026

Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript

Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 6, 2026

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the second quarter ended June 30, 2026. “This is a pivotal time for the CHD community, when availability of new therapies could improve awareness, testing and access to care. At EASL, experts emphasized that achieving durable suppression of hepatitis delta virus to undetectable levels is a key predictor of improved clinical outcomes for people with CHD. Our.

Business Wire • Aug 5, 2026

Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates

Vir Biotechnology, Inc. (VIR) came out with quarterly earnings of $0.47 per share, missing the Zacks Consensus Estimate of $0.83 per share. This compares to a loss of $0.8 per share a year ago.

Zacks Investment Research • Aug 6, 2026

Vir Biotechnology Announces Chief Financial Officer Transition

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed Interim Principal Financial Officer, effective July 23. Jason O'Byrne is leaving the Company to pursue another opportunity and will remain with Vir Biotechnology through August 3 to ensure a smooth transition. The Company has initiated a comprehensive search to identify its next Chief Financial Officer."Brent has deep in.

Business Wire • Jul 24, 2026

Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 5 to provide a corporate update and discuss its financial results for the second quarter ended June 30, 2026. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website.About Vir BiotechnologyVir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powe.

Business Wire • Jul 22, 2026

Vir Biotechnology: Multiple Catalysts In Hepatitis And Oncology Ahead

Vir Biotechnology is entering a catalyst-rich period with key clinical trial readouts from the ECLIPSE program in hepatitis delta plus updates from its T-cell engagers in oncology indications. VIR has partnered with Astellas Pharma to develop VIR-5500, its masked PSMA-targeting T-cell engager for prostate cancer. Updated data from VIR-5818 are due in H2'26 and could include a further ~18 months of data.

Seeking Alpha • Jul 16, 2026

Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. “We are pleased to welcome Tim to Vir Biotechnology's Board of Directors at a pivotal moment for the company,” said Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, Vir Biotechnology. “Tim brings a strong background of strategic discipline and operational insight that has he.

Business Wire • Jun 10, 2026

Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta at the upcoming EASL Congress 2026 in Barcelona, Spain, May 27-30, 2026. Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: Week 96 endpoint results from the Phas.

Business Wire • May 18, 2026

Vir Biotechnology: Trading Near Cash Value With A Huge Revenue Opportunity

Vir Biotechnology is rated a buy, supported by a strong cash position, pivotal late-stage pipeline, and deep institutional backing. VIR's lead CHD drugs, Tobevibart and Elebsiran, target a large, underserved market with potential for high margins and accelerated regulatory approval. The Astellas partnership secures funding for oncology development, extends the cash runway into 2028, and minimizes dilution risk ahead of key catalysts.

Seeking Alpha • May 16, 2026